October 21, 2016 10:06 PM ET


Company Overview of Mesoblast Limited

Executive Profile

Jonathan Richard Symonds CBE, BA, FCA

Head of Corporate Finance & Strategy, Mesoblast Limited
AgeTotal Calculated CompensationThis person is connected to 5 Board Members in 5 different organizations across 12 different industries.

See Board Relationships


Mr. Jonathan Richard Symonds, CBE, BA, FCA also known as Jon, serves as Head of Corporate Finance & Strategy at Mesoblast Limited. Mr. Symonds serves as Senior Advisor at GHO Capital Partners LLP. He serves as the Chief Financial Officer at Novartis Institutes for BioMedical Research, Inc. since September 1, 2009. He serves as Deputy Chief Financial Officer at Novartis Vaccines and Diagnostics, Inc. He joined Mesoblast as an advisor in 2014. He served as the Chief Financial ...

Corporate Headquarters

55 Collins Street
Melbourne, Victoria 3000


Phone: 61 3 9639 6036
Fax: 61 3 9639 6030

Board Members Memberships

Independent Non-Executive Director, Chairman of Group Audit Committee and Member of Conduct & Values Committee
Chairman and Chairman of Chairman's Nominations & Remuneration Committee
Chairperson, Member of Compensation Committee and Member of Nominating & Corporate Governance Committee


BA 1980
University of Hertfordshire

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

There is no Total Compensation data available.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup


Dominick C. Colangelo Esq.Chief Executive Officer, President, Treasurer and Director
Vericel Corporation
Gil Van Bokkelen Ph.D.Co-Founder, Chairman and Chief Executive Officer
Athersys, Inc.
David A. Dresner Interim Chief Executive Officer and Interim President
Osiris Therapeutics, Inc.
Christian Homsy M.D., MBAChief Executive Officer and Executive Director
Celyad SA
Compensation as of Fiscal Year 2015.

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Mesoblast Limited, please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.